ArticlePain and therapy2023

Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia.

Takahiro Ushida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.